.png)
Agenzia Italiana del Farmaco
home
Highlights
-
18 May 2026
Press releases
New medicines for type 2 diabetes and obesity: AIFA guide to responsible use
AIFA produced the guide “New medicines for diabetes and obesity: what you need to know for informed use” (also available as a public information leaflet), which provides an up-to-date and comprehensive overview of safety profile, authorised therapeutic indications, consumption trends and correct clinical use of these medicines.
-
07 May 2026
Press releases
AIFA and AIOM strengthen their collaboration on Monitoring Registries: a joint table to make the most of ‘real-world’ data in oncology
The initiative is part of activities aimed at promoting the appropriate use of medicines and supporting, through structured analysis, the planning, evaluation and governance of regulatory aspects of medicines, as well as the production of scientific evidence of high clinical value.
-
30 Apr 2026
Monitoring pharmaceutical expenditure
AIFA Monitoring of Pharmaceutical Expenditure: January-October 2025
"Monitoring of national and regional pharmaceutical expenditure, January-October 2025" presented to the AIFA Board of Directors.
-
29 Apr 2026
Monitoring pharmaceutical expenditure
AIFA Publishes the Third Position Paper on Biosimilar Medicines: Interchangeability, Informed Switching and NHS Sustainability
The new text was approved by AIFA’s Scientific and Economic Committee (CSE), discussed within the AIFA-Regions Working Group.
News
18 May 2026
The Agency
Italian Medicines Agency's online services will be unavailable due to scheduled maintenance
15 May 2026
Transparency Lists
AIFA updates the Transparency Lists
14 May 2026
Lists of Class A and Class H medicinal products
List of class A and H medicinal products at 30 November 2025
12 May 2026
Safety of medicinal products
Direct Healthcare Professional Communication (DHPC) on Ontozry (cenobamato)
07 May 2026
Safety of medicinal products
Direct Healthcare Professional Communication (DHPC) on Adalain
07 May 2026
Consumption and pharmaceutical expenditure
Procedure for the review and validation of lists of therapeutic indications for innovative medicines by pharmaceutical companies
FarmaciLine
Questions regarding drug efficacy, safety and availability
TOLL-FREE NUMBER
Services
Interactive OsMed - The use of medicines in Italy
An interactive consultation of data on the use of medicines in Italy in the general and regional population, described in terms of expenditure, volumes, typology
Media
